Response to Comments: MolDX: EndoPredict® Breast Cancer Gene Expression Test

This document (A58752) is a response to comments about the MolDX EndoPredict Breast Cancer Gene Expression Test and does not itself define coverage, limitations, or documentation requirements. For the policy details, required documentation, and effective coverage rules refer to LCD L37663 (MolDX: EndoPredict), notice period beginning 2021-05-20 and effective date 2021-07-04.

"This document is a response to provider comments regarding the MolDX EndoPredict Breast Cancer Gene Expression Test and does not itself specify coverage criteria or claim documentation requirements..."

Sign up to see full coverage criteria, indications, and limitations.